Avantax Advisory Services Inc. Acquires 1,840 Shares of DexCom, Inc. (NASDAQ:DXCM)

Avantax Advisory Services Inc. grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 34.4% during the fourth quarter, Holdings Channel reports. The firm owned 7,184 shares of the medical device company’s stock after purchasing an additional 1,840 shares during the period. Avantax Advisory Services Inc.’s holdings in DexCom were worth $559,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter worth about $25,000. Private Trust Co. NA boosted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Larson Financial Group LLC grew its holdings in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter worth $38,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of DexCom during the 4th quarter worth $49,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In related news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last quarter. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DXCM shares. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group upped their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and increased their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $73.80 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a market capitalization of $28.84 billion, a P/E ratio of 51.61, a P/E/G ratio of 2.30 and a beta of 1.28. The business has a 50-day moving average price of $83.33 and a two-hundred day moving average price of $76.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.